Key facts
- This page summarizes Jared Kelly's Form 4 filing for ONCOLYTICS BIOTECH INC (ONCY).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Mar 2026, 08:00.
Jared Kelly - 12 Mar 2026 Form 4 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ONCY
- Reported as of
- 12 Mar 2026
- Net transaction value
- +$4,848
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2026, 08:00:01 UTC
- Prior SEC filing
- 13 Feb 2026
- Next SEC filing
- 03 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kirk Look, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jared Kelly filed Form 4 for ONCOLYTICS BIOTECH INC (ONCY) on 13 Mar 2026.
Change
- Previous filing in this sequence was filed on 13 Feb 2026.
- Current net transaction value: +$4,848.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002103581
Primary reporting owner
Kelly Jared
- Relationship
- Chief Executive Officer, Director
- Address
- C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO
- Signature
- /s/ Kirk Look, Attorney-in-Fact
- Signature date
- 13 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONCY
transaction
Common Shares
Purchase
- Transaction value
- $4,848
- Shares
- +5,050
- Change %
- +4.6%
- Price
- $0.9600
- Shares after
- 114,050
- Date
- 12 Mar 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.